These data suggested that lnc-TCL6 could be used as an effective biomarker for predicting LC from healthy and HBV-infection groups but a poor diagnostic marker for HBV-infection groups compared with healthy individuals. Here, TCL6 is linked to laryngotracheoesophageal cleft.